Fig. 2.

42-year-old female with unilateral left axillary adenopathy noted 5 days after receiving the second dose of the Pfizer-BioNTech COVID-19 vaccine in her left upper extremity, which improved on follow-up targeted ultrasound performed 4 weeks after initial presentation and ultimately resolved on follow-up targeted ultrasound performed 12 weeks after initial presentation. (a) Gray-scale and (b) color Doppler images demonstrate an enlarged left axillary lymph node with cortical thickening (arrow). (c) Gray-scale and (d) color Doppler images from a targeted ultrasound performed 4 weeks after initial presentation demonstrated interval decreased cortical thickening of the left axillary lymph node (arrow). (e) Gray-scale and (f) color Doppler images from a targeted ultrasound performed 12 weeks after initial presentation demonstrated interval resolution of the previously noted left axillary adenopathy (arrow).